LGM
KROS icon

Logos Global Management’s Keros Therapeutics KROS Stock Holding History

Logos Global Management’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-850,000
Closed -$13.4M – 81
2025
Q3 		$13.4M Sell
850,000
-1,150,000
-58% -$17M 1.33% 32
2025
Q2 		$26.7M Hold
2,000,000
– – 3.57% 8
2025
Q1 		$20.4M Buy
+2,000,000
New +$23.2M 3.62% 8
2021
Q4 		– Sell
-15,000
Closed -$593K – 71
2021
Q3 		$593K Buy
+15,000
New +$534K 0.04% 54
2021
Q1 		– Sell
-450,000
Closed -$31.7M – 64
2020
Q4 		$31.7M Sell
450,000
-1,150,000
-72% -$72.5M 2.76% 8
2020
Q3 		$61.7M Buy
1,600,000
+1,200,000
+300% +$47.6M 7.9% 2
2020
Q2 		$15M Buy
+400,000
New +$12.3M 3% 14

Other funds holding KROS

BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $127B AUM 43.98% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return